Skip to content
Screener

ADMA Biologics ADMA Q2 2025 earnings

Reported August 6, 2025 · After market close

Revenue$122.0MMiss by $8.3M
EPS$0.15Beat by $0.01
Revenue estimate$130.3M
EPS estimate$0.14

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$138.1M
EPS estimate$0.19

Financials

Q2 2025

Income statement

See full
Revenue$122.0M+13.8%
Gross profit$67.2M+17.0%
Operating income$42.8M+9.2%
Net income$34.2M+6.7%
EPS (diluted)$0.14+7.7%

Balance sheet

See full
Cash & equivalents$90.3M+2.3%
Total debt$10.4M+1.0%
Total equity$398.3M+112%
Total assets$558.4M+48.3%

Cash flow

See full
Operating cash flow$21.1M-53.7%
CapEx$2.4M+17.2%
Free cash flow$18.7M-57.1%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$4.26B+64.4%
Enterprise value$4.18B+66.3%
P/E20.4×-54.1×
P/S9×+1.1×

Profitability

See full
Gross margin53%+6.9pp
Operating margin32.8%+7.4pp
Net margin44.1%+33.5pp
FCF margin13.9%-6.3pp

Returns & leverage

See full
Return on equity71.2%+50.5pp
Debt / equity0×0.0×
Current ratio5.3×-1.5×

Segments

By product

See full
ASCENIV$83.3M+39.1%
BIVIGAM$37.7M—
Intermediates And Other$917.0K—

By segment

See full
ADMA Bio Manufacturing$121.9M+14.8%
Plasma Collection Centers--100%

By geography

See full
US$122.0M—

FAQ

When did ADMA Biologics report Q2 2025 earnings?
ADMA Biologics (ADMA) reported Q2 2025 earnings on August 6, 2025 after market close.
What were ADMA Biologics's Q2 2025 revenue and EPS?
ADMA Biologics reported revenue of $122.0M and eps of $0.15 for Q2 2025.
Did ADMA Biologics beat estimates in Q2 2025?
Revenue missed the consensus estimate of $130.3M by $8.3M. EPS beat the consensus estimate of $0.14 by $0.01.
How did ADMA Biologics's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 13.8% from $107.2M a year earlier and eps grew 15.4% from $0.13.
Where can I find ADMA Biologics's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001140361-25-029143) and the 10-Q periodic report (0001140361-25-029177) directly on SEC EDGAR. The filing index links above go to sec.gov.